Psychedelic Spotlight Interview with Anthony Tennyson
In this episode of the Psychedelic Spotlight podcast, we feature…
Psychedelic Spotlight News
Psychedelic Spotlight Interview with Daniel Carcillo
In this episode of the Psychedelic Spotlight podcast, we catch…
Psychedelic Spotlight Interview with James Hallifax
In this episode of the Psychedelic Spotlight podcast, we feature…
Tim Ferriss and Michael Pollan Team Up to Launch UC Berkeley Psychedelic Journalism Fellowship
Podcaster and author of “The 4-Hour Work Week” will gift the university’s Center for the Science of Psychedelics $800,000 over 3 years to fund fellowship overseen by Professor Pollan.
Interview with Doug Drysdale, CEO, Cybin Inc
Doug talks about the company’s mission to revolutionize mental healthcare, how Cybin is delivering powerful and effective therapies, and why being the first psychedelic-based company to list on the New York Stock Exchange was a natural fit. Cybin can be found on the NYSE under the ticker symbol $CYBN.
Psychedelic Drug Use Among College Students Increased During Covid-19 Pandemic
Annual survey finds college students drank less during the pandemic, in favor of smoking more marijuana and experimenting with hallucinogens.
Detroit Voters Can Decriminalize Psychedelic Plants This November
The proposal asks voters if the city should “decriminalize to the fullest extent permitted under Michigan law the personal possession and therapeutic use of entheogenic plants by adults.”
BREAKING NEWS: Psychedelics ETF, PSIL, to launch THIS WEEK
BREAKING NEWS: Advisor Share Psychedelic Medicines ETF, PSIL, is going live THIS WEEK!!!!
Investing in ETFs can be a good way for retail investors to cash in on the shroom boom. This actively managed ETF will be managed by professionals who will do research on which companies have scientific and financial advantages.
PSIL will be on the NYSE, and will most likely feature companies such as MindMed (MNMD), Compass Pathways (CMPS), atai Life Sciences (atai), Numinus (NUMI) and more.
It will be a pure play psychedelics medicines ETF, and will not include marijuana companies (YAY). This means companies working with LSD, MDMA, Psilocybin and more. Primarily it is focused on improving mental health, so tackling problems like depression, PTSD addiction and more
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#AdvisorShares #PSIL #ThePsychedelicInvestor
Hallucinogen Persisting Perception Disorder Is a Psychedelics Problem Ehave Wants to Solve
“HPPD is a discomfort. Some people have it for 10, 15, 20 years and they regret the day they did the drug that caused it,” says the CEO of Ehave.
UW-Madison Study Aims to Increase Minority Representation in Psychedelic Clinical Trials
“Certain demographic groups have been the recipients of more legal scrutiny related to substance use than the majority of the population,” says lead researcher Cody Wenthur.
End of content
End of content